Sector
1063 stories · page 49 of 54
The group has obtained a long-term supply of psilocybin under a Drug Enforcement Administration schedule I license for psilocybin-based studies
The Vancouver-based company is 'actively engaged' in pursuing new avenues of distribution both in North America and internationally
He will champion the company’s Novoformulations-branded delivery systems for the pharmaceutical, nutraceutical and psychedelic medicine industries
Skin Elements and Holista Colltech recently signed a binding agreement to launch a natural alcohol-free hand sanitiser.
The firm's acquisition of AltMed Capital gives it a fully operational ketamine clinic and cutting-edge intellectual property
The California company's proprietary platform Parallax Care tracks patients’ vital signs for adherence to their medical and drug regimens
Investors can pre-register for the Life Sciences Investor Forum — there are no costs to log-in, attend the live presentations or ask questions
The company is also providing immediate access to Personal Protection Equipment such as medical masks and protective sterile gowns
Those with severe cases of the virus experience pneumonia that can progress to acute respiratory distress syndrome (ARDS)
It expects this to be the first of thousands of patients dosed with the FDA approved drug in the coming years
Velinoff Pharma will promote and distribute the CholBiome and CholBiomeX3 brands, which contain the company’s LPLDL probiotic bacteria strain
Its goal is to forge an array of regional and global partnerships to bring sugarBEAT to market
It cited a recent study that looked at samples from patients with severe pneumonia resulting from the virus
The update was provided alongside news the group had applied to the US regulator to add a further nine people to its phase I/IIa clinical study
The announcement comes after data from Part 1 demonstrated that MAT2203 was safe and well-tolerated
The company is focused on the commercialisation of its technology in the US and advancing regulatory submissions in other territories.
The company is developing and commercialising antisense pharmaceuticals for large unmet markets. Antisense therapy is a form of treatment for genetic disorders or infections.
CEO Mark Emalfarb said the company applies its proprietary C1 gene expression platform to speed up the development of vaccines, drugs
THC has the potential to cultivate cannabis in over 100,000 square metres of hydroponic greenhouse facilities in Australia at its Bundy, Eden Farms and Ballina sites.
The license gives Nabis the ability to manufacture its own CBD oil extracts for its BIS and BIS+ line of products